- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06478056
Correlation of Portal and Peripheral Venous ctDNA in Pancreatic Adenocarcinoma (VEINOPAN)
Study Overview
Detailed Description
Pancreatic adenocarcinoma is the 6th most common cancer in France and is expected to be the 2nd leading cause of cancer mortality in Europe by 2030. Its overall 5-year survival for all stages combined is estimated at 7-8%.
Surgery is the only potentially curative treatment for pancreatic adenocarcinoma (PA), although only 10-20% of patients present with resectable disease. The oncological results of surgery alone are disappointing (median overall survival (OS) of 15-20 months and 5-year OS of 8-15%), due to the high frequency of recurrence. For this reason, surgery must be integrated into a comprehensive treatment sequence, also known as multimodal therapy.
Significant progress has been observed over the past 5 years, with a marked increase in median OS in recent clinical trials, and an intensification of perioperative chemotherapy (CT) protocols.
Liquid biopsy and circulating biomarkers show promise for improving the multidisciplinary approach to treatment of pancreatic adenocarcinoma.
Circulating tumor DNA (ctDNA) is the most extensively studied marker in blood liquid biopsies and can provide insight into the molecular profile and individual characteristics of the tumor. This could pave the way for the identification of new therapeutic targets and markers of tumor response to complement diagnosis and provide improved stratified treatment. Similarly, the measurement of tcDNA in peritoneal fluid could provide a better understanding of individual tumour characteristics and the risk of peritoneal metastasis.
It is important to assess whether portal venous ctDNA is likely to provide distinct information from peripheral venous ctDNA; if the two ctDNAs are highly correlated, then it seems unlikely that one can provide complementary information to the other.
In addition, our work would evaluate the prognostic impact of the detection of circulating tumor DNA in portal venous blood collected intraoperatively, as well as its detection in peritoneal fluid.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Pauline TORTAJADA, Dr
- Phone Number: +33 02 32 88 40 00
- Email: pauline.tortajada@chu-rouen.fr
Study Contact Backup
- Name: julie Rondeaux, Dr
- Phone Number: +33 02 32 88 54 27
- Email: julie.rondeaux@chu-rouen.fr
Study Locations
-
-
-
Rouen, France, 76031
- Recruiting
- University Hospital, Rouen
-
Contact:
- Julie RONDEAUX
- Phone Number: 02 32 88 54 27
- Email: julie.rondeaux@chu-rouen.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
- Patient with operable pancreatic adenocarcinoma (resectable or boderline with or without neoadjuvant therapy) with histological evidence or indirect diagnostic criteria (CA 19-9 Significant (≥ 200 U/ml), pancreatic hypodense lesion without differential diagnosis)
- Biological criteria: Neutrophils > 1,500 cmm, platelet count > 100,000 cmm, creatinine clearance (Cockroft and Gault equation) > 60 ml/min, hemoglobin > 10 g/dl.
- ECOG performance status 0 or 1
- Patient has read and understood the information letter and signed the non-opposition/consent form.
- For an adult unable to give consent: Representative of the adult who has read and understood the information letter and signed the consent form
Exclusion Criteria:
- Other active cancer or haematological malignancy
- Uncontrolled congestive heart failure - untreated angina pectoris; recent myocardial infarction (within the last year) - uncontrolled hypertension (SBP > 160 mm or DBP > 100 mm, despite optimal drug therapy), long QT.
- Uncontrolled major infections, chronic infectious diseases, immunodeficiency syndromes
- Premalignant hematological disorders, e.g. myelodysplastic syndrome
- Severe hepatic impairment
- Patients not registered with social security
- Pregnant, parturient or breast-feeding woman (a pregnancy test will be carried out unless there is a history of hysterectomy, tubal ligation or menopause)
- Person deprived of liberty by an administrative or judicial decision, or person placed under court protection, sub-guardianship or guardianship.
- History of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol, or to prevent him/her from giving informed consent.
- Treatment contraindicated for venous sampling
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Surgery
patients operated on for pancreatic adenocarcinoma in the digestive surgery department of Rouen University Hospital
|
patients operated on for pancreatic adenocarcinoma in the digestive surgery department of Rouen University Hospital
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
level of ctDNA
Time Frame: Surgery
|
the level of ctDNA measured in peripheral venous and portal blood before and after mobilization of the specimen during surgery
|
Surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
level of ctDNA
Time Frame: surgery
|
ctDNA levels measured in peripheral venous and portal blood before and after mobilization of the specimen during surgery
|
surgery
|
peritoneal ctDNA level
Time Frame: surgery
|
ctDNA levels measured in peritoneal fluid during surgery.
|
surgery
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021/0385/HP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
City of Hope Medical CenterRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditionsKorea, Republic of, United States, Japan
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Shanghai Zhongshan HospitalFudan UniversityNot yet recruitingPancreatic Cancer Stage III | Pancreatic Cancer, Stage IB | Pancreatic Cancer, Stage IIA | Pancreatic Cancer, Stage IIBChina
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer
-
National Cancer Institute (NCI)CompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of Wisconsin, MadisonCompletedStage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
Clinical Trials on pancreatectomy
-
Hospital General Universitario de AlicanteNot yet recruitingSurgery--Complications | Pancreatic Fistula | Pancreas Disease
-
First Affiliated Hospital, Sun Yat-Sen UniversityUnknownPancreatic Neuroendocrine Tumor
-
Azienda Policlinico Umberto ICompleted
-
Technische Universität DresdenWithdrawnPancreatic TumorGermany
-
National Cheng-Kung University HospitalCompleted
-
Fudan UniversityRecruitingPancreatic Cancer | Surgery | LaparoscopyChina
-
Yonsei UniversityTerminatedDuctal Adenocarcinoma | Left-sided Pancreatic CancerKorea, Republic of
-
University Hospital, MontpellierAIDS Malignancy ConsortiumActive, not recruitingPancreatic Ductal AdenocarcinomaFrance
-
Asan Medical CenterOlympusCompletedBenign Neoplasm of Body of Pancreas | Benign Neoplasm of Tail of Pancreas